Related Experiment Video
Updated: Sep 8, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership
Tess Harris1, Hannah R Bridges2, Wendy D Brown3
1Polycystic Kidney Disease Charity, London, UK tess.harris@pkdcharity.org.uk.
Insights
Autosomal dominant polycystic kidney disease (ADPKD) research priorities were identified by patients, carers, and healthcare professionals. Top concerns include slowing disease progression and improving early treatment and care organization for better outcomes.
Area of Science:
- Nephrology
- Genetics
- Public Health
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, causing 7-10% of kidney failure cases.
- Current research on ADPKD is extensive, but funding allocation lacks clear priorities.
- A priority setting partnership was established to identify and rank key research uncertainties in ADPKD care.
Purpose of the Study:
- To identify and prioritize research questions in Autosomal dominant polycystic kidney disease (ADPKD) care.
- To involve patients, carers, and healthcare professionals in setting research priorities.
- To guide future research funding for ADPKD to maximize improvements in patient outcomes.
Main Methods:
- Adapted James Lind Alliance (JLA) methodology was employed.
- Uncertainties in ADPKD care were identified from literature and refined into indicative questions.
- A survey and online consensus workshop involving patients, carers, and healthcare professionals established the top 10 research priorities.
Main Results:
- 117 uncertainties were refined into 35 indicative questions, with 17 shortlisted via survey.
- The top 10 research questions were agreed upon by workshop participants.
- Key priorities focused on slowing ADPKD progression, identifying candidates for early treatment, and optimizing care organization.
Conclusions:
- The identified priorities reflect the multifaceted challenges of living with and treating ADPKD.
- Future ADPKD research funding should align with these patient- and clinician-identified priorities.
- Focusing on these key areas can maximize improvements in ADPKD outcomes.
Objectives:
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney condition, accounting for 7%-10% of patients with kidney failure. Fundamental basic science and clinical research on ADPKD is underway worldwide but no one has yet considered which areas should be prioritised to maximise returns from limited future funding. The Polycystic Kidney Disease Charity began a priority setting partnership with the James Lind Alliance (JLA) in the UK in 2019-2020 to identify areas of uncertainty in the ADPKD care pathway and allow patients, carers and healthcare professionals to rank the 10 most important questions for research.
Design:
The scope covered ADPKD diagnosis and management, identifying new treatments to prevent/slow disease progression and practical, integrated patient support (https://pkdcharity.org.uk/research/for-researchers/adpkd-research-priorities). We used adapted JLA methodology. Initially, an independent information specialist collated uncertainties in ADPKD care from recent consensus conference proceedings and additional literature. These were refined into indicative questions with Steering Group oversight. Finally, the 10 most important questions were established via a survey and online consensus workshop.
Setting:
UK.
Participants:
747 survey respondents (76% patients, 13% carers, 11% healthcare professionals); 23 workshop attendees.
Results:
117 uncertainties in ADPKD care were identified and refined into 35 indicative questions. A shortlist of 17 questions was established through the survey. Workshop participants reached agreement on the top 10 ranking. The top three questions prioritised by patients, carers and healthcare professionals centred around slowing disease progression, identifying persons for early treatment and organising care to improve outcomes.
Conclusions:
Our shortlist reflects the varied physical, psychological and practical challenges of living with and treating ADPKD, and perceived gaps in knowledge that impair optimal care. We propose that future ADPKD research funding takes these priorities into account to focus on the most important areas and to maximise improvements in ADPKD outcomes.
More Related Videos
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome II : Assessment and Medical Management
Nephrons
Chronic Kidney Disease II: Clinical Manifestations

